FibroGen, Inc. is a research-based pharmaceutical company focused on the discovery, development and commercialization of novel therapeutic agents to treat serious unmet medical needs. The Company has a global approach to the development and commercialization of its products.

Current Report (Form 8-K | Period ending 2024-12-16)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Fibrogen Inc (FGEN US)

Current Report (Form 8-K | Period ending 2024-12-16)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-12)

Current Report (Form 8-K | Period ending 2024-09-27)

Current Report (Form 8-K | Period ending 2024-09-12)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)